In recent years, therapeutic antibody drugs have become one of the fastest growing fields in the biopharmaceutical industry. With the development of technology, various forms of engineered antibodies have been constructed to improve their performance, including affinity maturation, Fc engineering, humanization, bispecific or multi-specific antibodies (CrossMab, BiTE, etc.), chimeric antigen receptors (CAR), etc.

By using the DimAb^® antibody development platform and in combination with the predictive bioinformatic analysis, DIMA Biotechnology can provide services for therapeutic antibody drug development, including antibody humanization, CAR and bispecific antibody molecule construction, etc.